Integra LifeSciences and Johnson and Johnson (J&J) have decided to divest five neurosurgical medical device product lines to Natus Medical to settle a complaint filed by the Federal Trade Commission (FTC).
The complaint was filed against Integra’s proposed $1bn acquisition of J&J’s Codman Neuro division and stated that the deal would have a negative impact on neurological devices market in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As per the Commission, the impacted device markets would include intracranial pressure monitoring, cerebrospinal fluid collection and fixed-pressure valve shunt systems, non-antimicrobial external ventricular drainage catheters, and dural grafts.
In the country, Integra and Codman account for 94% of the intracranial pressure monitoring systems market, 71% of the cerebrospinal fluid collection systems, 46% of the non-antimicrobial external ventricular drainage catheters, 38% for fixed pressure valve shunt systems, and 75% for dural grafts.
A consent agreement signed by Integra and J&J allows the Commission to monitor compliance with the orders on divestment.
Integra and J&J entered a binding offer in February for the Codman Neurosurgery business, which includes hydrocephalus, neuro-critical care, and operative neurosurgery devices.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe devices are expected to complement Integra’s portfolio of tissue ablation, dural repair, and cranial stabilisation products, allowing it to offer the entire range of neurosurgical solutions.
